New Discoveries in Multiple Sclerosis Highlight SPT Week in Review

5. PARP Inhibitor Treatment Shows Promise for Patients with Small Cell Lung Cancer

The addition of the poly ADP-ribose polymerase (PARP) inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC), according to recent data from a phase 2 clinical trial. Read more.

4. Moving Health Care into the Future: Proposal for Pharmacist-led Refill Authorizations

Pharmacist-led refill authorizations are a practical solution to the nation’s health care crisis, helping to improve quality while reducing costs as well as saving physicians’ time. Read more.

3. Body Mass Index Associated with Risk of Secondary Progressive Multiple Sclerosis

Although high body mass index (BMI) is known to be associated with the development of multiple sclerosis (MS), it is unknown whether BMI also affects the conversion to the progressive form of the disease. Read more.

2. FDA Restricts Use of Keytruda, Tecentriq in Certain Patients Due to Efficacy Issues

Officials with the FDA are restricting the use of pembrolizumab (Keytruda, Merck) and atezolizumab (Tecentriq) in certain patients with urothelial cancer due to an efficacy issue identified in clinical trials. Read more.

1. Novel Mechanism of Demyelination Discovered in Multiple Sclerosis

Blocking a type of cell death that occurs in multiple sclerosis (MS) could be a way to reduce demyelination and neurodegeneration, potentially leading to new therapeutic targets, according to a new study. Read more.